SNCA and Parkinson disease: EGCG, quercetin, and kaempferol have all been shown to exhibit anti-amyloidogenic properties; thus, their employment within PD treatment may result in the attenuation of α-synuclein aggregation within the body and the pathologic effects induced by their presence.